Author: Himanshu Patni
12 August 2023
Platinum-based ovarian cancer treatment refers to the use of chemotherapy drugs that contain platinum to treat ovarian cancer. Platinum drugs, such as cisplatin and carboplatin are effective at killing cancer cells by damaging their DNA and preventing them from dividing. In the North American region, the demand for the Platinum-based ovarian cancer treatment market is growing at a significant rate, and it is estimated that it will grow rapidly during the projected timeframe.
Access sample report (including graphs, charts, and figures): https://univdatos.com/get-a-free-sample-form-php/?product_id=43018
The platinum based ovarian cancer treatment market in North America has grown significantly due to the increasing number of ovarian cancer and its high death tolls in the country becomes an important factor in the market growth of platinum-based ovarian cancer treatment in the nation. For instance, as per the Canadian Cancer Society, around 3,000 Canadian women will be diagnosed with ovarian cancer in 2022 and an estimated 1,950 will die from it. The 5-year net survival for ovarian cancer is 45%. This means that about 45% of women diagnosed with ovarian cancer will survive for at least 5 years. The U.S. is the leading player in healthcare and the presence of well-established healthcare and research infrastructure in the country is attributed to the frequent product launches of new and advanced medication in the oncology category including platinum-based ovarian cancer treatment drugs. As a result, the U.S. acquires a prominent market for platinum-based ovarian cancer treatment. For instance, in November 2022, ImmunoGen announced the FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer.
Further, the North America Platinum Based Ovarian Cancer Treatment Market is expected to grow at a strong CAGR of 19.0% during the forecast period (2022-2030). Overall, the market for Platinum Based Ovarian Cancer Treatment in North America has grown due to the increasing cases of ovarian cancer and the region’s growing need for platinum based drugs.
Based on the drug type, the market has been categorized into cisplatin and carboplatin. Among them, the cisplatin segment is expected to grow at the highest CAGR in the market. In the case of certain forms of ovarian cancer, particularly those that are platinum-sensitive, cisplatin is superior to carboplatin in terms of therapeutic efficacy which is likely to boost the growth of the segment. For instance, according to the Journal of Clinical Oncology in 2020, cisplatin was found to be more effective than carboplatin in treating advanced ovarian cancer in patients who had not previously received platinum-based chemotherapy.
Based on the dosage form, the market has been categorized into intravenous powder and intravenous solution. Among them, the intravenous solution segment is expected to grow at a higher CAGR in the market. Intravenous solutions are more convenient to use than intravenous powders. For medical professionals who need to administer the medication quickly and effectively, they can be a big advantage because they don’t need any additional preparation time or steps
For a detailed analysis of the Global Platinum Based Ovarian Cancer Treatment Market browse through –https://univdatos.com/report/platinum-based-ovarian-cancer-treatment-market/
Global Platinum Based Ovarian Cancer Treatment Market Segmentation
Market Insight, by Drug Type
· Cisplatin
· Carboplatin
Market Insights, by Dosage Form
· Intravenous Powder
· Intravenous Solution
Market Insights, by End-Users
· Hospital
· Cancer Research Institutes
· Others
Market Insight, by Region
· North America
o U.S.
o Canada
o Rest of North America
· Europe
o Germany
o UK
o France
o Spain
o Italy
o Rest of Europe
· APAC
o China
o Japan
o India
o Rest of APAC
· Rest of the World
Top Company Profiles
· Eli Lilly and Co
· Bristol-Myers Squibb Co
· Novartis AG
· Pfizer Inc.
· Roche Holding AG Genussscheine
· AstraZeneca
· Merck KGaA
· Johnson & Johnson
· Sanofi SA
· GlaxoSmithKline plc.
Get a call back
